Patient coaching to help people keep taking abemaciclib for early breast cancer
Tests standardized coaching to support people with early breast cancer taking abemaciclib.
Plain-language title generated from the registry record
Registry title: IMPLEMENTING PATIENTS' COMPETENCE IN ORAL EBC THERAPY PERSISTENCE
Key facts
- Where
- Aschaffenburg, Bergisch Gladbach, Erlangen, Esslingen am Neckar, Itzehoe, Kulmbach, Lübeck, and Wilhelmshaven, GermanySee the 8 sites
Where in Germany
- MVZ am Klinikum Aschaffenburg GmbHAschaffenburg, GermanyTaking people
- Evangelisches Klinikum Bergisch Gladbach, GynäkologieBergisch Gladbach, GermanyTaking people
- Department of Obstetrics and GynaecologyErlangen, GermanyTaking people
- Klinikum Esslingen, Frauenheilkunde und GeburtshilfeEsslingen am Neckar, GermanyTaking people
- Klinikum Itzehoe, Holsteinisches BrustzentrumItzehoe, GermanyTaking people
- Klinikum Kulmbach, BrustzentrumKulmbach, GermanyTaking people
- Universitätsklinikum Schleswig-Holstein, Klinik für Frauenheilkunde und Geburtshilfe (Gynäkologie)Lübeck, GermanyTaking people
- MVZ für Onkologie und Urologie GmbHWilhelmshaven, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Institut fuer Frauengesundheit
- Trial code
- NCT07521202
- Record updated
- 4 November 2026
- Original description
The goal of this interventional study is to evaluate the effect of standardized patient coaching on treatment adherence among patients taking abemaciclib.Read full original descriptionShow less
A Scientific Study Evaluating Therapy Persistence in Patients With Hormone Receptor-positive, HER2-negative Early Breast Cancer Under Adjuvant Treatment With Abemaciclib Who Receive Standardized Patient Education and Counselling.
The goal of this interventional study is to evaluate the effect of standardized patient coaching on treatment adherence among patients taking abemaciclib.
The main question it aims to answer is, whether standardized coaching leads to patients taking abemaciclib much more consistently. Researchers will therefore compare therapy adherence of patients receiving standardized coaching to patients receiving routine care.
Participants will be asked to answer several questionnaires.
Inclusion: Women age 18 or older at time of ICF signature; Patients with HRpos/HER2neg early breast cancer who are treated with oral, commercially available prescribed abemaciclib in combination with endocrine therapy. Patients can be included if abemaciclib therapy was started no more than 28 days ago; Patients treated with abemaciclib according to the SmPC and each center´s medical practice; Informed consent given prior to the starting study activities.
Exclusion: Women who are pregnant or lactating; Patients with contraindications against abemaciclib according to the current SmPC; Patients who are not eligible for the study due to severe comorbidities, unavailability or any other relevant reason according to the treating physician.